Cannalean Biotechs

About

Q&A

What is Cannalean Biotechs' primary focus?

Cannalean Biotechs is a clinical-stage biotechnology company developing an innovative CBD-based solution for lowering cholesterol and triglycerides, aiming to address hyperlipidemia.

When was Cannalean Biotechs founded?

Cannalean Biotechs was founded in 2018.

Where is Cannalean Biotechs headquartered?

Cannalean Biotechs is headquartered in Tel Aviv, Israel.

What is the core technology behind Cannalean Biotechs' product?

The core technology is a proprietary oral formulation, CLC-01, which combines Cannabidiol (CBD) and Chitosan, protected by patents in multiple countries.

Who is the founder and CEO of Cannalean Biotechs?

David Bassa is the Founder & CEO of Cannalean Biotechs, appointed in November 2017.

Does Cannalean Biotechs have any strategic affiliations?

Yes, Cannalean Biotechs has a strategic affiliation with Clalit Health Services, Israel's largest healthcare organization, through its commercialization arm Mor Research Applications, which holds a minority stake.

What markets does Cannalean Biotechs target?

Cannalean Biotechs targets the global pharmaceutical and wellness markets, focusing on patients with hyperlipidemia.

What is the status of Cannalean Biotechs' product development?

Cannalean Biotechs is a clinical-stage company, and its proprietary formulation, CLC-01, has shown promising results in preclinical models and human feasibility studies.

Team · 7

David Bassa

Founder · Founder & CEO

Ofer Alshech

CFO

Guy Defrin

COO

Dr. Dror Robinson

CMO

Prof. Moshe Mittelman

CSO

Dr. Sari Prutchi Sagiv

CTO

Dr. Noah Ben Shalom

Chief Chemist

Sectors & technology